Commercial Partnerships
Cancer Research UK’s Commercial Partnerships team, formerly known as Cancer Research Technology (CRT), develop and commercialise exciting new discoveries in cancer research. Our deep understanding of both academia and industry enables us to translate promising research into commercial propositions for the greatest patient benefit and maximum financial return.
Exclusive rights to over £450m of cancer research in FY19/20
10 cancer drugs to market, including Rubraca, Zytiga, Lynparza, Balversa
We speak your language
Cancer Research UK's Commercial Partnerships team translates academic research into industry propositions.
£20m in grants and support leveraged in FY19/20
If a project looks promising, we’ll find a way to move it forward.
Realising clinical and commercial potential
We’re driven to achieve maximum patient benefit and market value.
Many projects, one focus: cancer
Our specialism means we’re more experienced, more knowledgeable and better connected.
CRUK Therapeutic Discovery Laboratories principal focus is on establishing and prosecuting biologically-themed multi-project alliances with industry to deliver breakthrough medicines for cancer patients.
With exclusive rights to more than £450m of world-class cancer research a year, we’re the gateway to much of the high quality oncology research happening in the UK today.
Do you have an idea or a discovery with commercial potential? Are you interested in working with industry? Our team can help develop the most promising projects.
| 12 November 2021 | Syncona's Autolus in $250m funding deal with Blackstone Life Sciences |
| 9 November 2021 | Artios Pharma: Taking on DNA repair to tackle cancer |
| 27 October 2021 | Takeda to acquire Cancer Research UK’s spinout GammaDelta Therapeutics |
Increase your life sciences reagent portfolio quickly and easily.
Discover licencing opportunities for unique research tools from 130+ institutes worldwide.
We've established major partnerships with research institutions, pharmas and biotechs of all sizes.
